Skip to content

Effect of Melissa officinalis (Lemon Balm) in Postmenopausal women with symptoms.

Efficacy of Badranjboya in Postmenopausal Syndrome: A Randomized Placebo-Controlled Study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/01/079124
Enrollment
60
Registered
2025-01-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N951- Menopausal and female climactericstates

Interventions

Intervention1: Badranjboya (Melissa officinalis L.): The drug will be pounded, sieved and mixed well to make a homogenous powder. Five grams will be administered daily orally for 8 weeks. Control In

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All postmenopausal women (at least 1 year without menstrual cycle) with any postmenopausal symptoms as per Modified Kupperman Index scale (MKI) greater than or equal to 7 Women with Pittsburgh Sleep Quality Index score greater than or equal to 5 Women with psychological menopausal symptoms as per Depression, Anxiety and Stress Scale (DASS-21 scale). All postmenopausal women with follicle stimulating hormone (FSH) greater than 30 IU/ml.

Exclusion criteria

Exclusion criteria: Women with undiagnosed vaginal bleeding, surgical menopause (bilateral oophorectomy) and malignancies. Use of hormone therapy or oral contraceptives within two months. Women with co-morbidities such as uncontrolled hypertension (Stage 2 hypertension more than 140/90 mmHg), uncontrolled diabetes mellitus (FBS more than 130mg/dl or PPBS more than 180 mg/dl or RBS more than 200mg/dl or HbA1c more than 7.00 percent), uncontrolled hypothyroid. Women with extremely severe psychological menopausal symptoms with DASS-21 scores for Depression more than 28, Anxiety more than 20 and Stress more than 34. Women with obstructive sleep apnea, restless leg syndrome, parasomnia, substances use such as alcohol or on sleeping pills. Women with diagnosed psychiatric diseases

Design outcomes

Primary

MeasureTime frame
Change in Modified Kupperman Index questionnaireTimepoint: 4, 8, 12 and 16 weeks

Secondary

MeasureTime frame
Change in DASS-21, PSQI, & Palpitation as per MKI score. Timepoint: At baseline week 8 & 16 weeks

Countries

India

Contacts

Public ContactArshiya Sultana

National Institute of Unani Medicine

samanfatma828@gmail.com08007473956

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026